Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.

Front Oncol · 2018 · PMC5894159 · PMID 29670855

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Three trials (TANDEM, EGF30008 , and ELECTRA) showed that addition of HER2-targeting to endocrine treatment significantly prolongs PFS, although the OS improvements in these trials did not reach statistical significance ( 70 , 71 , 92 , 93 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.